MiRagen Therapeutics (Viridian Therapeutics)
Have updates for this profile? Please contribute data
= Subscriber Access Only
You are viewing a preview of this profile. Request a Preqin Pro demo for full access to all profiles and underlying data.
With Preqin Pro, you gain an unobstructed view of all alternative asset class activity across institutional investors, fund managers, funds, portfolio companies, deals, exits, and service providers.
MiRagen Therapeutics (Viridian Therapeutics) - overview
Established
2007
Location
Waltham, MA, US
Primary Industry
Biotechnology
About
Founded in 2007 and based in Colorado, US, Viridian Therapeutics, Inc. formerly known as MiRagen Therapeutics, Inc. operates as a biotechnology company that develops cardiovascular and muscle disease therapeutics based on microRNA biology. In January 2024, Viridian Therapeutics, Inc.
raised USD 150 million in a private placement, selling 7. 14 million shares at USD 21 per share on the Nasdaq Global Select Market under the ticker symbol VRDN. The firm, as of July 2024, has offices in Massachusetts and Colorado, US, and is led by its President and CEO, Steve Mahoney. Viridian Therapeutics develops therapies for patients with autoimmune and rare diseases.
The company's portfolio includes a pipeline of investigational therapeutic candidates. Central to their efforts is a focus on thyroid eye disease (TED), exemplified by their candidate, VRDN-001, currently in pivotal Phase 3 trials (THRIVE and THRIVE-2). These studies aim to evaluate the drug's efficacy and safety for patients with active and chronic TED. Additionally, VRDN-003, another candidate, offers a promising subcutaneous therapy option, with plans underway for its own Phase 3 program (REVEAL-1 and REVEAL-2).
Other pipeline products include VRDN-006 and VRDN-008, which hold potential across multiple autoimmune diseases. The company plans to utilize the January 2024 funding to further its clinical development programs, as well as for working capital and general corporate purposes.
Current Investors
Atlas Venture, Boulder Ventures, JAFCO Group
Primary Industry
Biotechnology
Sub Industries
Molecular Science, Genetics & Gene Therapy, Biopharmaceuticals
Website
www.miragen.com
Company Stage
Series C
Total Amount Raised
Subscriber access only
MiRagen Therapeutics (Viridian Therapeutics) - deals
| Deals Type | Deal Status | Target (s) | Deal Date | Investor(s) | Seller(s) | Deal size (Mn) | Enterprise value (Mn) | Post-money valuation (Mn) | EBITDA multiple (x) | Revenue multiple (x) | Lead partner (s) |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Private Placement/Follow on | Completed | MiRagen Therapeutics (Viridian Therapeutics) | - | ||||||||
| PIPE | Completed | MiRagen Therapeutics (Viridian Therapeutics) | - |
Displaying 1 - 2 of 2
Time to go Pro
Get Preqin Pro for unrestricted access to 600,000+ detailed profiles on fund managers, investors, funds, companies, and other alternative asset players. Unlock exclusive data on future plans, company financials, fundraising history, track records, and more.